Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P < 0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used.

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon / Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, Laura; Farinati, F.; Giannini, E. G.; Tovoli, Francesco; Ciccarese, Federica; Rapaccini, G. L.; DI MARCO, Mariacristina; Caturelli, E.; Zoli, Marco; Borzio, F.; Virdone, R.; Marra, Fabio; Felder, M.; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F. G.; Olivani, A.; Masotto, ANDREA-ELEONORA; Nardone, G.; Colecchia, Antonio; Persico, M.; Boccaccio, V.; Craxì, A.; Bruno, Samantha; Trevisani, Franco; Cammà, C.; the Italian Liver Cancer Group:, [. . .; Biselli, Maurizio; Caraceni, Paolo; Cucchetti, Alessandro; Domenicali, Marco; Piscaglia, Fabio; Gramenzi, Annagiulia; Granito, Alessandro; Magalotti, Donatella; Serra, Carla; Negrini, Giulia; Napoli, Lucia; Salvatore, Veronica; Benevento, Francesca; Sacco, ROSALIA ROSALBA; Olmi, S; Dall'Aglio, Ac; Feletti, V; Stefanini, Gf; Golfieri, R; Mosconi, C. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 45:1(2017), pp. 160-168. [10.1111/apt.13821]

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

DI MARCO, MARIACRISTINA;COLECCHIA, ANTONIO;
2017

Abstract

Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P < 0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used.
2017
45
1
160
168
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon / Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, Laura; Farinati, F.; Giannini, E. G.; Tovoli, Francesco; Ciccarese, Federica; Rapaccini, G. L.; DI MARCO, Mariacristina; Caturelli, E.; Zoli, Marco; Borzio, F.; Virdone, R.; Marra, Fabio; Felder, M.; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F. G.; Olivani, A.; Masotto, ANDREA-ELEONORA; Nardone, G.; Colecchia, Antonio; Persico, M.; Boccaccio, V.; Craxì, A.; Bruno, Samantha; Trevisani, Franco; Cammà, C.; the Italian Liver Cancer Group:, [. . .; Biselli, Maurizio; Caraceni, Paolo; Cucchetti, Alessandro; Domenicali, Marco; Piscaglia, Fabio; Gramenzi, Annagiulia; Granito, Alessandro; Magalotti, Donatella; Serra, Carla; Negrini, Giulia; Napoli, Lucia; Salvatore, Veronica; Benevento, Francesca; Sacco, ROSALIA ROSALBA; Olmi, S; Dall'Aglio, Ac; Feletti, V; Stefanini, Gf; Golfieri, R; Mosconi, C. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 45:1(2017), pp. 160-168. [10.1111/apt.13821]
Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, Laura; Farinati, F.; Giannini, E. G.; Tovoli, Francesco; Ciccarese, Federica; Rapaccini, G. L.; DI MARCO, Mariacristina; Caturelli, E.; Zoli, Marco; Borzio, F.; Virdone, R.; Marra, Fabio; Felder, M.; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati Baroni, G.; Foschi, F. G.; Olivani, A.; Masotto, ANDREA-ELEONORA; Nardone, G.; Colecchia, Antonio; Persico, M.; Boccaccio, V.; Craxì, A.; Bruno, Samantha; Trevisani, Franco; Cammà, C.; the Italian Liver Cancer Group:, [. . .; Biselli, Maurizio; Caraceni, Paolo; Cucchetti, Alessandro; Domenicali, Marco; Piscaglia, Fabio; Gramenzi, Annagiulia; Granito, Alessandro; Magalotti, Donatella; Serra, Carla; Negrini, Giulia; Napoli, Lucia; Salvatore, Veronica; Benevento, Francesca; Sacco, ROSALIA ROSALBA; Olmi, S; Dall'Aglio, Ac; Feletti, V; Stefanini, Gf; Golfieri, R; Mosconi, C
File in questo prodotto:
File Dimensione Formato  
Petta_et_al-2017-Alimentary_Pharmacology_&_Therapeutics.pdf

Accesso riservato

Dimensione 271.04 kB
Formato Adobe PDF
271.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1257967
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 70
  • ???jsp.display-item.citation.isi??? 67
social impact